Abstract Number: 090 • 2023 Pediatric Rheumatology Symposium
Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience
Background/Purpose: The management of pediatric rheumatic disease has been forever changed by the advent of biologic drugs and the pursuit of targeted therapy. There is…Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…Abstract Number: 076 • 2023 Pediatric Rheumatology Symposium
COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Background/Purpose: Psychological symptoms are common in childhood-onset systemic lupus erythematosus (cSLE) and may impact other psychological and health-related outcomes. Mental health problems such as anxiety…Abstract Number: 134 • 2023 Pediatric Rheumatology Symposium
Patient-Provider Communication in Pediatric Rheumatology
Background/Purpose: Communication is an essential part of medical care, especially in Pediatric Rheumatology where children have varying complex chronic diseases. However, there is paucity of…Abstract Number: 137 • 2023 Pediatric Rheumatology Symposium
Geographic Mapping of Adolescents with Rheumatic Disease: Racial and Ethnic Diversity by Texas County
Background/Purpose: Rheumatic disease disproportionately impacts specific racial and ethnic groups frequently, resulting in health care inequities. Health care disparities are prevalent within certain geographic areas…Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…Abstract Number: 133 • 2023 Pediatric Rheumatology Symposium
An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients
Background/Purpose: Adolescents with chronic disease often struggle with the transition from pediatric to adult healthcare leading to poor follow-up and negative health outcomes. Social determinants…Abstract Number: 121 • 2023 Pediatric Rheumatology Symposium
The Effectiveness of Tonsillectomy in Periodic Fever, Aphthous Ulcer, Pharyngitis, and Adenitis Syndrome in Pediatric Patients
Background/Purpose: Periodic Fevers with Aphthous Ulcers, Pharyngitis, and Adenitis Syndrome (PFAPA Syndrome) is the most common pediatric periodic fever syndrome. The most recent diagnostic criteria…Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium
Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…Abstract Number: 124 • 2023 Pediatric Rheumatology Symposium
JIA-Associated TMJ Arthritis, Idiopathic Condylar Resorption or Anterior Disc Displacement – a Care Provider Survey
Background/Purpose: The temporomandibular joint (TMJ) can be affected in juvenile idiopathic arthritis (JIA) patients of any age or subtype. There have been reports of isolated…Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…Abstract Number: 128 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a novel clinical entity presenting following SARS CoV2 infection. This study describes a subgroup of MIS-C patients…
- « Previous Page
- 1
- …
- 543
- 544
- 545
- 546
- 547
- …
- 2607
- Next Page »
